Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
SAVA - Cassava Sciences, Inc.
Market Cap 875.90M P/E - EPS this Y 23.70% Ern Qtrly Grth -
Income -15.37M Forward P/E -11.66 EPS next Y 54.80% 50D Avg Chg -9.00%
Sales - PEG -0.21 EPS past 5Y 58.11% 200D Avg Chg -25.00%
Dividend N/A Price/Book 4.29 EPS next 5Y 83.80% 52W High Chg -59.00%
Recommedations 3.00 Quick Ratio 3.93 Shares Outstanding 47.98M 52W Low Chg 25.00%
Insider Own 11.86% ROA -37.43% Shares Float 42.38M Beta -0.62
Inst Own 29.11% ROE -8.35% Shares Shorted/Prior 15.91M/17.68M Price 20.98
Gross Margin - Profit Margin - Avg. Volume 840,450 Target Price 103.00
Oper. Margin - Earnings Date Nov 5 Volume 525,756 Change -3.94%
Healthcare | Biotechnology | United States
About Cassava Sciences, Inc.

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Cassava Sciences, Inc. News
11/29/24 Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & More
11/26/24 A Post-Mortem on Cassava Sciences
11/26/24 SAVA Stock Plunges 84% on Alzheimer's Drug Failure in Late-Stage Study
11/26/24 Down -83.93% in 4 Weeks, Here's Why You Should You Buy the Dip in Cassava Sciences (SAVA)
11/25/24 Cassava Sciences Plummets 84% After Embattled Alzheimer's Drug Flops
11/25/24 Cassava Sciences plummets over 80% on Alzheimer's trial fail
11/25/24 Cassava Sciences stock plummets after Phase III Alzheimer’s fail
11/25/24 Cassava Sciences update: SAVA stock price collapses after much-criticized Alzheimer’s drug flops
11/25/24 Cassava Sciences Stock Slides 84% as Alzheimer’s Trial Fails
11/25/24 Cassava Sciences Alzheimer's Drug Fails To Hit Primary Goal In Pivotal Study, Pharma Halts Late-Stage Studies
11/25/24 Cassava Stock Plunges as Alzheimer's Drug Fails Late-Stage Study
11/25/24 Cassava Sciences Topline Phase 3 Data Did Not Meet Co-Primary Endpoints
08:01 PM Cassava Sciences to Hold Corporate Update on November 25th
11/18/24 Cassava Sciences Appoints Freda Nassif as Chief Commercial Officer
11/15/24 Is Cassava Sciences (SAVA) Outperforming Other Medical Stocks This Year?
11/12/24 What Makes Cassava Sciences (SAVA) a New Buy Stock
11/07/24 Cassava Sciences Reports Q3 2024 Financial and Operating Results
10/31/24 Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024
10/30/24 Institutions along with individual investors who hold considerable shares inCassava Sciences, Inc. (NASDAQ:SAVA) come under pressure; lose 6.7% of holdings value
10/28/24 MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
SCANNON PATRICK J MD PHD Director Director Jun 12 Option 0.95 1,000 950 1,000 06/12/23
BARBIER REMI President and CEO President and CEO May 24 Option 16.87 85,713 1,445,978 782,002 05/25/23
ROBERTSON SANFORD Director Director May 10 Option 17.64 9,284 163,770 856,851 05/10/23
BARBIER REMI President and CEO President and CEO Jun 06 Option 23.38 65,368 1,528,304 822,437 06/07/22
BARBIER REMI President and CEO President and CEO Apr 25 Option 8.63 49,460 426,840 376,112 04/25/22
GUSSIN ROBERT Z Director Director Mar 29 Option 21.95 7,470 163,966 12,434 03/29/22
ROBERTSON SANFORD Director Director Mar 25 Option 20.3 4,670 94,801 924,765 03/28/22